[Antitumour vaccination in patients with ENT tumours. Successful track record].
Dyckhoff
G
G
AG Molekulare Zellbiologie, Universitäts-Hals-Nasen-Ohren-Klinik Heidelberg. gerhard_dyckhoff@med.uni-heidelberg.de
Herold-Mende
C
C
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010039:Otorhinolaryngologic Neoplasms / Q000276:immunology* / Q000517:prevention & control*; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
Int J Immunopharmacol. 1999 Apr;21(4):241-52
10408632
Int J Cancer. 2000 May 1;86(3):368-74
10760825
Otolaryngol Head Neck Surg. 1998 Oct;119(4):412-7
9782004
ORL J Otorhinolaryngol Relat Spec. 1989;51(4):197-205
2664632
Acta Otolaryngol. 2002 Jul;122(5):546-52
12206267
Semin Oncol. 1998 Dec;25(6):677-96
9865682
Acta Otolaryngol. 1999 Mar;119(2):281-4
10320092
Cancer Res. 2004 Nov 1;64(21):8057-61
15520216
Mol Ther. 2001 Dec;4(6):551-8
11735339
N Engl J Med. 2004 May 6;350(19):1945-52
15128894